A new paper published on glenzocimab made @unibirmingham.
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy - Journal of Thrombosis and Haemostasis https://t.co/vR4BFsmFk0
[PRESS RELEASE] 📄
The University of Birmingham and Acticor Biotech announced the full regulatory approval of LIBERATE study, the first clinical trial evaluating glenzocimab for heart attacks ! 💔
👉 Further informations : https://t.co/Owo6UlnDk1
#PressRelease#biotech
The #VECTOR#trial compared a combined #EVT approach (stent retriever + contact aspiration) vs contact aspiration alone in patients with acute ischemic #stroke caused by red thrombi and assessed grade of reperfusion (eTICI score). Here are the #trial results at #ESOC2023 👇
[Live ESOC]
Day 2 : two @ActicorBiotech paper posters are available in the exhibition hall 📃
@ElieToledano, our Global Head of Project Coordination is waiting for you to discuss and answer your questions💬
#ESOC23#stroke#posters
The #TIMELESS#trial investigated if #tenecteplase administered in ischemic #stroke patients with large vessel occlusion presenting 4.5-24h after last known well improved functional outcome on the mRS at 90 days, compared to placebo. The results are presented now at #ESOC2023 👇
🇩🇪 [ESOC 23] 🇩🇪
Meet Acticor Biotech team at the European Stroke Organisation Conference 2023 in Munich - Germany, booth B1 ! 💡
The opportunity to discuss with our clinical and medical teams about glenzocimab and the ongoing clinical trials, over a coffee.
#stroke#ESOC23
🙏 Nous tenions à remercier Acticor Biotech pour leur soutien sur les Journées de la SFNV !
Venez les rencontrer et suivre leur session le jeudi 17 novembre
Pour vous inscrire https://t.co/mnoK9ouJ2w
Programme https://t.co/zl2nIPrmLv
#SFNV#neurovasculaire#ARS#paramédicale
Key message 2: Glenzocimab inhibits GPVI interactions with CRP, collagen, and fibrin by loss of dimerisation, conformational changes, and steric hindrance
Very happy to see our new paper on glenzocimab just published in Blood Advances! Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition https://t.co/BQzqQxuUmg
📈 HealthTech Innovation Days 📈
Meet Gilles Avenard - CEO, Sophie Binay, PhD - General Manager & CSO and Eric COHEN - CFO at the next HTI Days in Paris on October 13-14, 2022 !
👉More information : https://t.co/CoL7sdwuZe
#biotech#stroke#innovation#healthtech
Today is World Thrombosis Day #WTDay22! Thrombosis affects all of us and is responsible for many cardiovascular emergencies, such as stroke! Prevention & diagnosis are key to prevent serious illnesss! Spread the awareness! @isth@thrombosisday@ActicorBiotech
PRESS RELEASE 📃
Acticor Biotech announces the enrollment of the first US patient in its phase 2/3 study ACTISAVE for the treatment of stroke ! 🇺🇸🧠
👉 More informations : https://t.co/j0w7yJF6s1
#pressrelease#US#ACTISAVE#glenzocimab#biotech#stroke#healthcare